



Episurf Medical to present clinical data at Stora Aktiedagen, Stockholm, on November 13

Episurf Medical (NASDAQ: EPIS B) will present clinical data at the event Stora Aktiedagen, Stockholm, on November 13. The presentation will be given by CEO Pål Ryfors and Prof. Leif Ryd, Senior Medical Advisor. The results that will be presented are summarized below. The results show the same trends as previously presented, but are now for larger cohorts.

The presently available clinical data for Episealer® patients will be presented. This comprises clinical data for 70 patients that have passed 12 months after Episealer® implantation, as well as data for 30 patients that have passed 24 months.

"We see that the Episealer® patients experience great improvements in the pain scale VAS as well as in the clinical knee score KOOS where pain, symptoms, activities of daily life, sport function and quality of life are evaluated. There is no sign of deteriorating results after longer follow-up.

Further, emerging long-term data from a 1st generation mini-metal knee implant shows that the revision incidence tapers off with time and a cohort of patients are excellent after 10-12 years. Our absolute assessment is that the Episealer® will show similar curves, although at a superior level with less revisions.

We are going from fiction to facts and can now say that we see signs of that a mini-metal implant like the Episealer® will help most patients over long periods of time. We are of course extremely happy to see this data that the Episealer® surgeons have provided us with. We see an implant survival curve that is very encouraging with a low implant revision rate that complements the fine clinical outcomes for overall highly satisfied Episealer® patients." comments Prof. Ryd.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel: +46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical's Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical's µFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.